These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38331350)

  • 41. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H.
    Imai H; Kato S; Sakamoto Y; Kakudo Y; Shimodaira H; Ishioka C
    Oncol Rep; 2014 Mar; 31(3):1043-50. PubMed ID: 24378760
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
    Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
    Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis.
    Lu X; Liu DP; Xu Y
    Oncogene; 2013 Jun; 32(23):2900-6. PubMed ID: 22824795
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Distinct TP53 Mutation Subtypes Differentially Influence Cellular Iron Metabolism.
    Clarke SL; Thompson LR; Dandekar E; Srinivasan A; Montgomery MR
    Nutrients; 2019 Sep; 11(9):. PubMed ID: 31500291
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic significance of CD117 expression and
    Luo Y; Huang W; Zhang H; Liu G
    Oncol Lett; 2018 May; 15(5):6161-6170. PubMed ID: 29616097
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer.
    Zhu L; Pan JN; Qian Z; Ye WW; Wang XJ; Cao WM
    Breast Cancer; 2022 Jan; 29(1):103-113. PubMed ID: 34403063
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
    Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
    Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
    Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
    Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells.
    O'Grady S; Crown J; Duffy MJ
    Med Oncol; 2022 Jul; 39(10):142. PubMed ID: 35834073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
    Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
    Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic alterations in sporadic triple negative breast cancer.
    Pop LA; Cojocneanu-Petric RM; Pileczki V; Morar-Bolba G; Irimie A; Lazar V; Lombardo C; Paradiso A; Berindan-Neagoe I
    Breast; 2018 Apr; 38():30-38. PubMed ID: 29202330
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.
    Allred DC; Clark GM; Elledge R; Fuqua SA; Brown RW; Chamness GC; Osborne CK; McGuire WL
    J Natl Cancer Inst; 1993 Feb; 85(3):200-6. PubMed ID: 8423624
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of TP53 gene mutation in blood of breast cancer patients based on circulating tumor DNA and its application in prognosis.
    Lu Q; Wei L; Cai S; Zhang Z; Zhang L
    Cell Mol Biol (Noisy-le-grand); 2023 Nov; 69(11):200-206. PubMed ID: 38015519
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
    Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
    Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. p53 Dysregulation in Breast Cancer: Insights on Mutations in the
    Steffens Reinhardt L; Groen K; Xavier A; Avery-Kiejda KA
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373225
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
    Liu B; Yi Z; Guan Y; Ouyang Q; Li C; Guan X; Lv D; Li L; Zhai J; Qian H; Xu B; Ma F; Zeng Y
    Cancer Med; 2022 Jul; 11(14):2767-2778. PubMed ID: 35393784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.